Is Skyrizi approved for treating psoriatic arthritis?

Yes, Skyrizi is approved in adults to treat:

• active psoriatic arthritis
• moderate-to-severe plaque psoriasis in people who are candidates for systemic (body-wide) therapy or skin phototherapy (ultraviolet light therapy)
• moderately to severely active Crohn's disease
• moderately to severely active ulcerative colitis in adults.

Skyrizi, from AbbVie, was approved by the FDA for psoriatic arthritis on January 21, 2022.

Skyrizi studies in psoriatic arthritis

The Skyrizi (risankizumab-rzaa) approval for psoriatic arthritis was supported by two Phase 3, placebo controlled studies, KEEPsAKE-1 and KEEPsAKE-2.

In these studies, adult participants treated with Skyrizi received 4 maintenance doses a year, after first receiving two starter doses. The study included patients who had an inadequate response to non-biologic disease-modifying antirheumatic drugs (DMARDs) and / or biologics.

Results demonstrated improved skin and joint symptoms and physical function at week 24 when compared to a placebo.

• In both studies, significantly more patients treated with Skyrizi achieved the primary endpoint ACR20 (a composite measure that captures at least a 20% improvement in swollen and tender joints, plus other measures) at 24 weeks when compared to the group that received placebo.
• Overall, 57.3% and 51.3% of patients receiving Skyrizi achieved ACR20 (a composite measure that captures at least a 20% improvement in swollen and tender joints, plus other measures) compared to 33.5% and 26.5% of those receiving placebo, respectively.

The sponsor reports that no new safety risks were observed in the psoriatic arthritis studies. Skyrizi can lead to serious side effects such as allergic reactions and increased risk of infections. The most common side effects include upper respiratory infections (13%), headache (3.5%), fatigue (2.5%), injection site reactions (1.5%), and tinea (fungal) infections (1.1%).

Psoriatic arthritis is an inflammatory arthritis associated with plaque psoriasis. Over 30% to 40% of people with plaque psoriasis may develop psoriatic arthritis. Common symptoms are pain, swelling and stiffness, fatigue and loss of ability to fully use the joint.

Other treatments approved by the FDA to treat psoriatic arthritis include:

• Cosentyx (secukinumab)
• Enbrel (etanercept)
• Humira (adalimumab)
• Otezla (apremilast)
• Remicade (infliximab)
• Rinvoq (upadacitinib)
• Selarsdi (ustekinumab-aekn)
• Stelara (ustekinumab)
• Taltz (ixekizumab)
• Tremfya (guselkumab)
• Xeljanz (tofacitinib)

This is not all the information you need to know about Skyrizi for safe and effective use and does not take the place of your healthcare provider's directions. Review the full product information and discuss any questions you have with your doctor or other health care provider.

Related questions

• What does psoriasis look like?
• How do you get psoriasis and is it contagious?
• How does Tremfya work to treat plaque and psoriatic arthritis?